Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Outstanding Shares Update - 9/27/21
https://www.otcmarkets.com/stock/tomdf/security
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
https://investor.todosmedical.com/news-events/press-releases/detail/136/todos-medical-receives-approval-by-amazon-to-sell-immune
Tollovid® and Tollovid Daily™ are now available for immediate purchase on Amazon.com
New York, NY, and Tel Aviv, ISRAEL, Sept. 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced that it has received approval from Amazon e-commerce platform to sell Tollovid® and Tollovid Daily™, the Company’s 3CL protease (MPro) inhibiting dietary supplements to support health immune function.
Amazon.com is an international e-commerce company that offers online retail shopping services. It is the largest e-retailer in the United States with $385 billion in annual sales in 2020. In response to the increasing demand for immune support products, Todos Medical launched Tollovid and Tollovid Daily™ initially via the Company’s www.mytollovid.com website. Todos expects to target upcoming family gatherings like Thanksgiving and Christmas where close contact makes it increasingly more important to inhibit 3CL protease in order to help support the immune system. Both Tollovid and Tollovid Daily have 60 caplets per bottle. Tollovid Daily was designed for a twice daily dosing schedule for the person on the go seeking daily immune support. Tollovid was designed for a 12 pills per day, 5-day dosing schedule when a person is seeking maximum immune support over that period.
“Having Tollovid and Tollovid Daily available on Amazon is a great outlet to expand the reach of our brand,” said Gerald Commission, CEO of Todos Medical. “Amazon is one of the largest, most well-known e-commerce platforms in the world giving our Tollovid products a greater level of notoriety, making them much easier to find and purchase with confidence. Along with our recent ability to accept cryptocurrencies through Coinbase Commerce at www.MyTollovid.com, we believe Amazon will further widen our appeal and help us capture significant market share in the dietary supplement market. We are confident that our Tollivid products will be a hit with consumers who understand the importance of 3CL protease inhibition to support immune function, especially heading into the close contact times of this end of year holiday season with Thanksgiving, Hanukkah, Christmas, other religious holidays and New Year’s Eve coming in the months ahead with immune health risks having increased dramatically. Our dietary supplement uses all natural ingredients, is vegan-friendly and has no known harmful side effects even at high dose levels. As the pharmaceutical industry has started to focus on 3CL science and its potential immune health benefits, Todos is positioned to capitalize with Tollovid products available on the market now, allowing breakthroughs in this important research area to help accelerate demand.”
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. In 20201, Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter.
Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic. The Joint-Venture is pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. The Company’s proprietary therapeutic candidate Tollovir™ is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to initiate Phase 2/3 clinical trials for both hospitalized and non-hospitalized patients in Israel.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States. The products cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
Good points on Tollivid, and I'm in agreement. I hope there is a massive news media and advertising campaign in the works to inform the public once the clinical data is released.
I have to disagree with the Iodine pills strategy. These pills saturate the thyroid with elemental (non-radioactive) Iodine so that in the event of a nuclear accident, there will be little or no update of radioactive Iodine in the thyroid. These pills serve ONLY this purpose, no other. This doesn't prevent the body from ingesting or absorbing other radionuclides which can cause damage to cells and organs. There is also the direct radiation exposure that can cause damage.
A dirty bomb uses a conventional explosive to contaminate a large area with radioactive material. The material of choice is Cesium-137 due to it's long half-life and high-energy gamma rays. Radioactive Iodines do not occur in nature, and are only produced in a nuclear fission reaction, i.e., nuclear power plant or nuclear detonation. Fission does not occur with a dirty bomb. Most of the radioactive Iodine nuclides have relatively short half-lives making them not the best choice for a dirty bomb. Also, the greatest impact of a dirty bomb isn't the death or injury by radionuclides, it's the fear and disinformation that is spread whenever there term "radioactive" is used. In that respect, it's more of an attack on the psyche than on the body.
Also, since the addition of Iodine in our table salt decades ago, the average person already has a saturated thyroid and the Iodine pills would provide peace of mind only and no real benefit, even after a nuclear accident. Our foods today are loaded with salt containing Iodine. However, governments are still obligated to dispense Iodine pills to the public in the event of a nuclear accident. The individual has the option to accept or decline (unlike the government's push for mandatory COVID-19 vaccinations).
Sorry to hear you don't agree with Generally Accepted Accounting Principles (GAAP). Nothing deceiving about reporting using accepted practices and certified by both CEO and CFO and reviewed by the company's auditing firm.
Generally Accepted Accounting Principles (GAAP or US GAAP) are a collection of commonly-followed accounting rules and standards for financial reporting. The specifications of GAAP, which is the standard adopted by the U.S. Securities and Exchange Commission (SEC), include definitions of concepts and principles, as well as industry-specific rules. The purpose of GAAP is to ensure that financial reporting is transparent and consistent from one organization to another.
Todos Medical Reports Second Quarter 2021 Financial Results
Company recorded positive earnings of $0.01 per share as financial condition improved
Corporate Highlights
Acquired Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test
Provista is a medical diagnostics company based in Alpharetta, Georgia that owns the intellectual property rights to the proprietary breast cancer blood test, Videssa®, and has a CLIA/CAP diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries. Todos Medical has begun ramping up Provista’s automated testing capacity as well as expanding its testing capabilities to include COVID variant testing and neutralizing antibody testing. When at full capacity the lab has automation in place to do up to 20,000 PCR tests, over 1,500 cPass neutralizing antibody tests, and 5,000 variant tests on a daily basis.
Videssa was developed to provide physicians with actionable information regarding breast cancer risk in women following an inconclusive mammogram result (BI-RADS III or IV), which primarily occurs in women with dense breasts. The results provided by the test have demonstrated specificity of 98%+ in both women over and under the age of 50 making it a powerful tool to help guide decisions of whether to continue to monitor patients intermittently, or whether to advance immediately into a more expensive and invasive diagnostic such as a breast biopsy. With breast biopsies having been found to show a false-positive rate following diagnostic screening procedures as high as 71 percent in the United States according to the National Cancer Institute, the annual cost in biopsy procedures that might have been avoided is estimated to be $2.18 billion. The Company sees a significant market opportunity for a breast cancer screening test for women under the age of 40 because current diagnostic tools do not recommend mammogram screening for this demographic. The dense breast population for which Videssa has been clinically validated also represents approximately 40% of mammogram recipients annually in the US.
Launched Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir™) in Hospitalized COVID-19 Patients
The trial is being conducted at Shaare Zedek Medical Center in Jerusalem, Israel to evaluate the safety and efficacy of Tollovir for the treatment of COVID-19 in hospitalized patients. Tollovir is a patent-pending therapeutic agent being developed through a joint venture between Todos Medical and NLC Pharma. 3CL protease inhibitors are targeted as desirable candidates for development of antiviral therapies against SARS-CoV-2 (the virus that causes COVID-19). Todos expects to provided interim data and to expand the study into India in the fourth quarter of 2021.
Receives FDA Certificate of Free Sale for New 5-Day Tollovid® Dosing Regimen
The US Food & Drug Administration granted the Company a new Certificate of Free Sale for a second dosing regimen for Tollovid™ as a dietary supplement. Under the new Certificate of Free Sale, the Company is authorized to market Tollovid with a dosing regimen of 60 pills over a five-day period, equivalent to 12 pills per day. Tollovid, a potent 3CL protease inhibitor botanical product, is a dietary supplement that helps to support and maintain healthy immune function.
Received Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
The patent application specifically covers methods for capturing consistent data from infrared spectroscopy readers, as well as the application of various artificial intelligence algorithm development methods to the data. The ability of TBIA to make a diagnosis of cancer has first been applied to the detection of breast and colon cancers, where Todos Medical has received CE Marks in Europe paving the way for commercialization initially focused on TMB-2 (dense breast / inconclusive mammogram secondary screening) and TMB-1 (general breast cancer screening) cancer detection tests.
"We made significant strides in the second quarter to position Todos for future growth on several fronts, including receiving $6.3 million in crossover investments led by Yozma Global Genomic Fund priced at $0.0599 per share," stated Gerald E. Commissiong, President and CEO of Todos Medical. "On the business front, first and foremost, the acquisition of Provista gives us the ability to establish a commercial ready test addressing a multi-billion market opportunity. It also provides us with a CLIA/CAP lab to drive growth in COVID-related testing as well as expanding into other high-volume testing through our automation capabilities. Second, the launch of our Phase 2 trial for Tollovir as a COVID antiviral candidate is a potential game changer for our company and we are excited about our plans to further expand the trial into India later this year. The receipt of additional certificates of free sale for our Tollovid in the second and third quarter also bolsters our ability to capitalize on 3CL protease inhibition in the immune support market. Lastly, the forwarding of our TBIA patent portfolio in Europe helps solidify our IP while we continue to develop this important diagnostic solution. As we move through the second half of 2021, we are focused on ramping testing volume at Provista, growing revenue at our COVID distribution business, and continuing the development and commercialization of our antivirals, supplements and diagnostic solutions. We also continue to work to position the company to achieve an uplisting to a national stock exchange. We are confident that this strategy will enable us to achieve significant long-term value for our stockholders."
Financial Highlights for Q2 2021
Revenues: Total revenue in the second quarter of 2021 was $1.7 million, a significant increase compared to revenue of $32,000 in the second quarter of 2020. The increase in revenue was due to sales from the Company’s COVID product distribution business.
Loss from Operations: The Company recorded an operating loss of $(1,662,0000) in the second quarter of 2021 compared to an operating loss of $(1.719,000) in the second quarter of 2020. The decrease in net loss was a result of increased gross margin dollars coupled with decreases in R&D expenses and sales and marketing expenses, partially offset by an increase in general and administrative expenses.
Net Income: The Company recorded net income of $3,390,000 in the second quarter of 2021 due to a $5,171,000 increase in financing expenses, net, compared to a net loss of ($2,585,000) in the second quarter of 2020. Net income per share in the second quarter of 2021 was $0.01 on 575.9 million weighted average shares outstanding compared to the second quarter of 2020 where the Company incurred a net loss of $(0.01) per share on 189.9 million weighted average shares outstanding.
Select Balance Sheet Items: The Company had cash of $308,000 and trade receivables of $1,792,000 as of June 30, 2021, compared to cash of $935,000 and trade receivables of$375,000 as of December 31, 2020. Total assets as of June 30, 2021, were $17,258,000 compared to $6,009,000 as of December 31, 2020. Shareholder deficit decreased to $(8,999,000) as of June 30, 2021, compared to $(11,001,000) as of December 31, 2020.
"While we achieved significant business milestones in the second quarter, we also witnessed several key improvements to our financial condition as well," said Daniel Hirsch, CFO of Todos Medical. "Our asset base was expanded significantly through our acquisition of Provista while our deficit decreased by $2 million, with a significant portion of our outstanding debt being convertible into preferred equity upon the Company’s uplisting to a national stock exchange. We expect further improvements to our balance sheet in the third quarter as we work to position the Company for a potential uplisting in the coming quarters."
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. In 20201, Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter.
Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic. The Joint-Venture is pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. The Company’s proprietary therapeutic candidate Tollovir™ is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to initiate Phase 2/3 clinical trials for both hospitalized and non-hospitalized patients in Israel.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States. The products cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
https://investor.todosmedical.com/news-events/press-releases/detail/135/todos-medical-reports-second-quarter-2021-financial-results
Form 8-K Filing
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-21-023531/0001493152-21-023531.pdf
On September 23, 2021, Todos Medical Ltd. (the “Company”) completed the conditions precedent required to enter into a Securities Purchase Agreement (the “SPA”) with an institutional investor (the “Purchaser”) pursuant to which the Company issued a promissory convertible note (the “Note”) to the Purchaser in the principal amount of $2,285,142.86 for proceeds of $2,000,000 (the “Transaction”). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of 4% per annum. The Note is convertible into shares of Common Stock (the “Conversion Shares”) at a conversion price of $0.0599 (the “Conversion Price). In addition, the Purchaser received a warrant (the “Warrant”) to purchase up to 11,924,636 shares of Common Stock (the “Warrant Shares”) of the Company with an exercise price equal to $0.107415 per share. The Warrant is exercisable for 5 years from the date of issuance. The Company intends to use the net proceeds from this Note to initiate Phase 2/3 trials for TollovirTM COVID- 19 patients, initiate digital marketing for its dietary supplement Tollovid®, increase sales & marketing for Provista Diagnostics, and for general corporate purposes.
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
New York, NY, and Tel Aviv, ISRAEL, Sept. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into an agreement with holders of the Company’s convertible notes that provides for a 90-day moratorium on conversions and a 90-day prohibition on sales of common shares by those noteholders issued as a result of conversion notices submitted after September 1st, 2021 (collectively the “Lockup”).
“We are very pleased to have received the support from our existing convertible note holders with this lockup agreement,” said Gerald E. Commissiong, President & CEO. “We have recently seen a significant increase in interest in the Company from individual and institutional investors as a result of significant advancements we have made in terms of our COVID related test offering at our highly automated CLIA/CAP lab Provista Diagnostics based in the Atlanta area. Moving forward, we expect even greater interest in our programs from the investment community as we make progress with our clinical-stage Tollovir® oral antiviral 3CL protease inhibitor therapeutic programs for both hospitalized and non-hospitalized patients, as well as our Tollotest™ companion biomarker that measures 3CL protease activity. We expect to release results later this quarter from an observational study Phase 1/2 study of Tollovir that was conducted in Israel in 2020, provide updates on the ongoing randomized, double-blind, placebo-controlled Phase 2 clinical trial in hospitalized COVID patients for Tollovir currently enrolling in Israel, as well as provide updates on the initiation of Phase 2/3 clinical trials planned for Tollovir in both hospitalized and non-hospitalized patients. We believe this lockup agreement will provide confidence to the marketplace, give the Company sufficient room to complete certain strategic transactions currently being evaluated to unlock shareholder value and help facilitate the listing of our common shares on a national stock exchange in the months ahead.”
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
https://investor.todosmedical.com/news-events/press-releases/detail/134/update-todos-medical-announces-90-day-moratorium-on
Not everyone has families with kids. Lots of single folks, widowers, couples with no kids, etc. I believe the demand will be higher than you think. Agreed, it's not for every budget, but it's an option that's available. For me, the better option is the Tollovid 5-day dosing regimen to have ready if needed. Overnight shipping is an option, so one could conceivably wait until they actually test positive to place their order and start the 5-day dose immediately upon receipt. No money spent until a confirmed positive test.
The IMMUNITY10 discount code also works for the single purchase of Tollovid Daily, dropping the price from $99 to $89.10. A monthly subscription to Tollovid Daily also drops the price 10% to $89.10 per month.
There's also the Tollovid Daily supplement that's $99 per bottle available on the MyTollovid.com web site. 60 capsules with daily dosage of 2 capsules/day. It's reported as half the dose of the Tollovid supplement which is more in line with the 5-day dosage used in the trials. $99 per month may still be too expensive for some, but it may be a better option than the $199 product.
Vaccines do not do the same thing as Tollovid. Tollovid is a 3CL Protease inhibitor, which prevents virus from replicating and allows the body's own immune system to defeat the virus. Vaccines will always be several steps behind whatever current mutation of the virus is dominant. That's recently been the "delta" variant, which has infected many people who were vaccinated. The current vaccines have been shown to be ineffective against the new "mu" variant.
British scientists have predicted the COVID-19 virus could continue to mutate into even more lethal variants for which the current vaccines are ineffective. Researchers will have to try to develop a new vaccine to combat these new variants, which means they will always be several steps behind the currently dominant variant. The virus will mutate much faster than vaccines can be developed and distributed. Antivirals such as Tollovir/Tollovid and the product Pfizer is testing disrupt the virus' ability to replicate, and will work for any variant that comes along.
We see the same behavior for the seasonal flu virus. The vaccines available each year are a sort of cocktail for the expected dominant variants for the upcoming flu season. Sometimes their predictions are off and the vaccine is less effective and some who are vaccinated still get the flu. A solution that stops the virus from replicating in the first place will be a better solution than a vaccine that may be targeting an earlier variant of the virus.
I purchased 2 bottles of Tollovid for my sister and brother-in-law. I'm purchasing a bottle for myself and one for my neighbor as well. None of us are going to take these daily, but having this supplement available will allows us to take the 5-day dosage as is being done in the trials if we test positive for COVID-19. That makes it a one-time cost every 2 years, which is the shelf-life of the supplement, and probably longer if refrigerated.
For each of us, this is a $199 insurance policy against dying from the COVID-19 coronavirus. I know quite a number of friends and coworkers who have died from this virus. For me $199 isn't too much to pay to ensure I survive if I test positive by eliminating the threat of the virus progressing to dangerous levels in my body.
Because I have signed up to receive news and updates from Todos Medical, I received an email with the discount code IMMUNITY10 that knocks 10% off the price purchased at MyTollovid.com.
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Consumers can subscribe for an auto-shipped supply of Tollovid Daily™ 3CL protease inhibitor for immune support every month
New York, NY, and Tel Aviv, ISRAEL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced an expansion of its Tollovid® dietary supplement 3CL protease (MPro) inhibitor immune support product line with the launch of Tollovid Daily™ via subscription. The subscription model takes the hassle out of remembering to order Tollovid Daily on a monthly basis.
Both Tollovid and Tollovid Daily are 3CL protease inhibitors for immune support that have 60 caplets per bottle. Tollovid Daily was designed as a twice-daily dosing schedule for people on the go that provides one month of daily immune support. Tollovid was designed as a 12 pills/day, 5-day dosing schedule for when a person is seeking maximum immune support over a short period of time.
“Tollovid Daily is an affordable immune support solution with mass market appeal,” said Gerald Commission CEO of Todos Medical. “We recently added the ability to accept payment via cryptocurrency on our www.MyTollovid.com e-commerce platform, and we think the Tollovid Daily subscription model appeals to consumers who are focused on automating their daily wellness routines. Our mission is to make our products available to anyone who wants them. We are making significant strides in making our products available via larger distribution channels, and we expect to provide further updates on this to the market shortly.”
Todos Medical featured on Proactive discussing cryptocurrency to purchase Tollovid & Tollovid Daily
Todos Medical featured on Good Day Chicago FOX 32
I believe the pieces are all there. Execution is the question. Lots of things have to go right and some are outside of the company's control. Even Edison had 1,000 unsuccessful attempts at the light bulb before success. I feel GC learned from his mistakes at Amarantus, and while a RS is likely inevitable for uplisting to Nasdaq, the balance sheet is a lot cleaner here with the convertible debt in the hands of a reputable VC firm who is interested in helping the company succeed.
The company can't execute a RS and then wait weeks or months for the Nasdaq uplisting to be approved. The shorts will kill the stock in the interim. The uplist only works if we meet the listing requirements, except for price, and can immediately uplist in conjunction with the RS so that the previous 30 days post-uplist price meets the minimum price requirements This has been successfully done by other companies.
GC tweeted this afternoon 10-Q expected tomorrow after close. Will post tweets later.
NEWS: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
New York, NY, and Tel Aviv, ISRAEL, Sept. 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a medical diagnostics and solutions company with comprehensive product offerings, today announced it has received a notice of allowance from the US Patent & Trademark Office (USPTO) for a trademark covering the Company’s proprietary 3CL protease inhibitor oral antiviral drug candidate NLC-V-01, also known as Tollovir™. In 2020, a Phase 1/2 clinical study evaluating the safety and efficacy of Tollovir in hospitalized patients was completed by the Company’s joint venture partner NLC Pharma Israel, and the Company and NLC are currently enrolling a Phase 2 clinical study in Israel in hospitalized patients. Pivotal Phase 2/3 clinical studies are currently being planned for both hospitalized and non-hospitalized patients.
“We are pleased with the speed with which the trademark for the brand name of our COVID-19 3CL protease inhibitor oral antiviral drug candidate Tollovir was issued,” said Gerald E. Commissiong, President & CEO of Todos Medical. “While we are pushing forward with our efforts to complete ongoing clinical studies in Israel and initiate pivotal studies in India, we are also very focused on engaging the US FDA to evaluate Tollovir potentially as part of the Emergency Use Authorization pathway in the United States. Results from the first clinical trial of Tollovir are being readied for release. We believe the USPTO moved quickly to authorize Tollovir’s trademark so that there would be a clear regulatory and marketing distinction with our dietary supplement product Tollovid®.”
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
https://investor.todosmedical.com/news-events/press-releases/detail/132/todos-medical-receives-trademark-notice-of-allowance-from
I guess I'm not understanding what investors are expecting beyond press releases, corporate updates, SEC filings, investor questions answered on Twitter and during online presentations. What kind of outreach am I missing?
Perhaps shareholders think they deserve answers such as this gem from a recent presentation:
Is Todos close to a partnership? "No comment" was Gerald's response.
Would shareholders prefer our CEO act like other penny stock CEOs by getting into emails and phone calls with individual investors, creating the perception that insider or privileged info is being delivered to a select few? If our CEO is doing that, I am unaware and I haven't seen any instances of it posted on this and other boards. I've known individuals who had private communications with penny stock CEOs. They recommended strongly I invest, but I said no thanks, and every one of those investments later went sub-penny. I wonder why. Maybe an unscrupulous CEO had something to do with it? The investor who contacted me was sure they had privy info that we could profit from.
There have been 46 Todos news releases in the past 12 months, including 5 corporate/strategic updates to investors. That averages to about 1 update per week. Investors questions are being answered on Twitter and in increasing numbers in the last several online presentations. How is this not providing an outreach to investors?
It's a serious question, and I don't feel I'm defending GC by pointing all of this out. It appears investors are getting as much info as is legally allowed. Just my opinion, of course. Investors will NEVER get all the info they want or desire. That's just the nature of investing, and in the penny stock world, it's more of a speculation than an investment given the greater risks involved.
Sep 17, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Sep 15, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep 13, 2021
Todos Medical to Present at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference) - Q&A session with investors for those who bothered to watch
Sep 01, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
Aug 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Aug 24, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Aug 23, 2021
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Aug 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
Aug 17, 2021
Todos to Present at Upcoming Emerging Growth Conference - Q&A session with investors at end
Aug 05, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug 02, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Jul 28, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
Jul 22, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
Jul 19, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
Jul 07, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
Jun 29, 2021
Todos Medical Provides End of Second Quarter 2021 Corporate Update
May 04, 2021
Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen
Apr 22, 2021
Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test
Apr 19, 2021
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
Apr 08, 2021
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
Apr 01, 2021
Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics
Mar 30, 2021
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Mar 29, 2021
Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY
Mar 23, 2021
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
Mar 17, 2021
Todos Medical Provides Corporate Update
Mar 12, 2021
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
Jan 25, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea
Jan 11, 2021
Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020
Dec 23, 2020
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Dec 02, 2020
Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020
Dec 01, 2020
Todos Medical Provides Strategic Outlook
Nov 24, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Nov 18, 2020
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay
Nov 17, 2020
Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs
Nov 13, 2020
Todos Medical CEO Provides Corporate Update
Nov 12, 2020
Todos Medical Announces $867,000 in Sales for October 2020
Oct 26, 2020
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
Oct 22, 2020
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
Oct 20, 2020
Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer
Oct 14, 2020
UPDATE: Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct 13, 2020
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct 07, 2020
Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health
Sep 30, 2020
Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States
Sep 25, 2020
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
Sep 22, 2020
Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million
Sep 18, 2020
Todos Medical CEO Releases Letter to Shareholders
An investor with so many doubts should probably sell their shares and move on. Good advice for TOMDF or any investment.
I post the CEO Twitter responses because some here (including yourself) are not signed up on Twitter. They provide another source of info not always available in the press releases or filings. Many of the CEO's tweets are in response to a shareholder question. I would think most shareholders would welcome these posts.
I also post news, filings, and updates to the outstanding share count. If that bothers you, feel free to place me on IGNORE. One could argue posting the ever increasing share count is NOT supporting GC. I'm being diluted along with everyone else.
I don't have answers to your questions. I'm as in the dark as most other shareholders and wait for news or updates to get my answers. Occasionally I have posted a question on Twitter to which GC has responded. Try it, you might get the answers you seek instead of relying on someone on this board to provide them to you.
But why make the effort if one continues to believe the CEO is lying to shareholders? Conversely, if someone believes in the future of the company or their products, they must be on the company payroll, right?
Refer to question 2. GC gave an update during the Q&A of the presentation.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165969066
I thought you were avoiding my Twitter posts, so why should they matter? You previously posted you didn't want to see GC's Twitter posts here.
Outstanding Shares Update - 9/17/21
https://www.otcmarkets.com/stock/tomdf/security
The last 13 minutes of the presentation is Q & A from investors. Worth watching. The following questions were asked:
1. Do you feel confident in your team to get the uplisting completed before the lock-up runs out? What's the chance of extending the lock-up if Nasdaq uplisting looks imminent?
2. Financials are late this quarter. What was the delay attributed to, and when do you anticipate they will be released?
3. Is the PCR and cPass scaleable? Why don't we have 6 to 10 of these labs spread across the country? Are we considering a JV with one of the big national labs?
4. There's chatter circulating that people are having trouble getting the cPass test from the Provista Diagnostics lab. Are you aware of this?
5. Are there currently any government programs that will drives sales of the cPass test, and are you aware of any future programs?
6. What does your typical customer look like who is ordering the cPass test?
7. Todos has been active in the press. Do you think there will be more coverage?
8. How soon will Tollovid be rolled out in Europe, Asia and the U.S.?
9. Regarding Tollovis, are you going to be ramping up marketing around it? Is supply chain in order for a mass marketing push?
10. Is Todos close to a partnership?
11. Where are we at with India clinical trials?
12. How is international distribution of traditional testing business going? What do you see is the most important part or partner necessary to ramp that up now?
Watch Todos Medical CEO Live on Good Day Chicago Saturday 7:40 CST.
He will discuss booster shots & cPass neutralizing antibody test.
LIVE LINK: https://fox32chicago.com/live
VIDEO: Todos Medical Ltd. Emerging Growth Conference 16 - September 15, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Cryptocurrency accepted include Bitcoin (BTC), Ethereum (ETH), Dogecoin (DOGE), Bitcoin Cash (BCH) and Litecoin (LTC)
New York, NY, and Tel Aviv, ISRAEL, Sept. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a medical diagnostics and solutions company with comprehensive product offerings, today announced that it is now accepting Bitcoin (BTC), Ethereum (ETH), Dogecoin (DOGE), Bitcoin Cash (BCH) and Litecoin (LTC) as payment for the Company’s proprietary 3CL protease inhibitor wellness products Tollovid® and Tollovid Daily™. The Company is able to accept these forms of payments through its www.mytollovid.com website when purchasers select Coinbase Commerce as the form of payment at checkout.
“We believe strongly that everyone should take Tollovid to support their immune function during times of significant immune challenge and should be taking Tollovid Daily each and every day in order to maintain consistent, healthy immune function,” said Gerald E. Commissiong, President & CEO of Todos Medical. “The ability to accept widely utilized cryptocurrency is an important step as we broaden our marketing efforts around our novel 3CL protease inhibitor wellness products.”
Tollovid and Tollovid Daily are dietary supplement products that have both received Certificates of Free Sale from the U.S. Food & Drug Administration (FDA), authorizing the marketing and sale of these products in the United States. The FDA has allowed the Company to make two specific claims with regards to each product:
1. Tollovid and Tollovid Daily help to support and maintain healthy immune function; and
2. Tollovid and Tollovid Daily are 3CL protease inhibitors.
Tollovid is targeted to customers that need maximum immune support, whereas Tollovid Daily addresses customers that require or could benefit from daily immune support. Both Tollovid and Tollovid Daily can be purchased via subscription and now, utilizing cryptocurrency.
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
https://investor.todosmedical.com/news-events/press-releases/detail/131/todos-medical-now-accepting-cryptocurrency-for-the-purchase
I posted a bunch of new GC tweets for you to enjoy. I'm sure they provide meaningful insights whether the board reader is a Todos shareholder or not.
So the post on 8/21/21 is not an indication that you sold your current small Todos investment?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165561229
A non-shareholder posting on a stock message board for a stock they once owned should probably take their own advice to Get a Life. Maybe focus on posting on boards for stocks they actually own. Unless all of their stock choices are losers and posting to trash the company and CEO is the only thing in their life they enjoy.